Posted by AGORACOM-JC
at 4:07 PM on Tuesday, September 21st, 2021
Kidoz (KIDZ: TSXV) owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss the entrance into lucrative teens and parents segment of soon to be $400 BILLION Mobile Ad Market.
We discuss:
New markets
Anticipated growth
Agencies that have already booked
+more
Q2 2021 highlights include:
Total Revenue of $2,177,505 – growth of 196% compared to Q2 2020 Total Revenue of $736,827.
AdTech revenue of $2,120,500 – growth of 247% compared to Q2 2020 AdTech Revenue $611,709.
Gross Profit of $1,024,333 – growth of 214% compared to Q2 2020 Gross Profit of $325,769.
EBITDA of $48,079 a 124% improvement from an EBITDA loss of ($197,057) in Q2 2020.
Sit back, relax and watch this powerful interview.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by returning guest, Vhari Macbeth to discuss psycholytic ketamine-assisted psychotherapy (KAP).
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company
The phase III study will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.
Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR said, “We need more innovation in this field and I’m hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.”
As psychedelics continue to break free from the stigma surrounding them, more and more people are seeing the promise these drugs have in changing the way we treat mental health. “Recent trials are showing that psychedelics are proving not only successful but also incredibly effective when stacked up against traditional forms of treatment, with one recent trial reporting that they are up to four times more effective than antidepressants.”
In a big step forward for psychedelic research, the DEA is set to increase limits for psilocybin. From the DEA: “DEA firmly believes in supporting regulated research of schedule I controlled substances.” We look forward to increased research and have a dedicated psychedelic contract research organization (CRO) in Cedar Clinical Research, capable of studying promising new treatments.
Posted by AGORACOM-JC
at 1:06 PM on Thursday, September 16th, 2021
PyroGenesis $PYR is the world leader in the development of advanced plasma processes and products. In short, their plasma torch technology has been the foundation of multiple successful applications around the world that significantly reduce both greenhouse gases and costs of doing business for some of the world’s biggest companies in these following verticals:
Ultra High-Tech 3D Printing (Additive Manufacturing)
Iron Ore Pelletization
Aluminum Smelters Recovery Of Dross
High-Purity Silicon For EV Batteries
….. Military Where Their Tech Sits On 4 US Aircraft Carriers.
Today’s $6 Million Plasma Torch Order Represents 4 Torches From Major Iron Ore Pelletizer Client “B”
“B” expects next orders to be for 130 torches
NPV estimate per torch is now $7M = $910,000,000
Client “A” has already requested a cost estimate for 36 torches
Discussions with Client “C” and many others are also taking place
HOW BIG IS THE OPPORTUNITY?
“The total world pellet production of 400 million metric tonnes of pellets represents a potential market for torch sales in excess of $10B worldwide. For reference, 40 million tonnes of CO 2 represent the combined yearly emissions of 8.7 million US passenger vehicles”
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders
We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.
CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.
Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.
BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.
This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”
Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.
Posted by AGORACOM-JC
at 4:40 PM on Wednesday, August 25th, 2021
Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders.
Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics
THE PROBLEM
● Depression and anxiety cost the global economy US$ 1 trillion each year
~ 20% of the world’s children and adolescents have a mental health condition
Suicide is the second leading cause of death among 15-29 year-olds
13% rise in mental health conditions & substance use disorders in last decade (to 2017)
Mental health conditions now cause 1 in 5 years lived with disability
#Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things
More than 80% of the global population prefers natural products as sources of new drug candidates …
and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals – creating drug therapies that harness the medicinal power of natural psychedelic compounds
1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022.
Sit back, relax and watch this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.
Posted by AGORACOM-JC
at 4:03 PM on Tuesday, August 24th, 2021
Kidoz owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss their stunning Q2 growth, and more.
Q2 2021 highlights include:
Total Revenue of $2,177,505 – growth of 196% compared to Q2 2020 Total Revenue of $736,827.
AdTech revenue of $2,120,500 – growth of 247% compared to Q2 2020 AdTech Revenue $611,709.
Gross Profit of $1,024,333 – growth of 214% compared to Q2 2020 Gross Profit of $325,769.
EBITDA of $48,079 a 124% improvement from an EBITDA loss of ($197,057) in Q2 2020.
Sit back, relax and watch this powerful interview.
